Preclinical evaluation of 177Lu-Nimotuzumab: A potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors

Denis Rolando Beckford Vera, Sebastian Eigner, Milos Beran, Katerina Eigner Henke, Alice Laznickova, Milan Laznicek, Frantisek Melichar, Marco Chinol

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: The humanized monoclonal antibody Nimotuzumab (h-R3) has demonstrated an exceptional and better clinical profile than other monoclonal antibodies for immunotherapy of epidermal growth factor receptor-overexpressing tumors. This work deals with the preparation and radiolabeling optimization of 177Lu-Nimotuzumab and their preclinical evaluation. Methods: Nimotuzumab was conjugated with S-2-(4-isothiocyanatobenzyl)-1,4,7,10- tetraazacyclododecane tetraacetic acid (p-SCN-Bn-DOTA), testing different molar ratios. The immunoconjugates were characterized. The radiolabeling with 177Lu was optimized. Radioimmunoconjugates stability was tested in 2-[bis[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid (DTPA) excess and human serum. In vitro studies were performed in tumor model cell lines. Receptor-specific binding was tested by competitive inhibition. 177Lu-Nimotuzumab in vivo studies were conducted in healthy and xenograft animals. Results: Nimotuzumab conjugates were obtained with high purity. Radiolabeling yield and specific activities ranged from 63.6% to 94.5% and from 748 to 1142 MBq/mg, respectively. The stability in DTPA excess and human serum was 95.9% and 93.2% after 10 days, respectively. The radioimmunoconjugate showed specific receptor binding in tumor cell lines. Biodistribution in healthy animals showed the typical behavior of the immunoconjugates based on monoclonal antibodies. The study in xenografts mice demonstrated uptake of 177Lu-Nimotuzumab in the tumor and reticuloendothelial organs. Conclusions: 177Lu-Nimotuzumab was obtained with high purity and specific activities under optimal conditions without significant loss in immunoreactivity and might be a potential radioimmunoconjugate for radioimmunotherapy of tumors with epidermal growth factor receptor overexpression.

Original languageEnglish
Pages (from-to)287-297
Number of pages11
JournalCancer Biotherapy and Radiopharmaceuticals
Volume26
Issue number3
DOIs
Publication statusPublished - Jun 1 2011

Fingerprint

Radioimmunotherapy
Immunoconjugates
Epidermal Growth Factor Receptor
Neoplasms
Pentetic Acid
Tumor Cell Line
Heterografts
Monoclonal Antibodies
Antibodies, Monoclonal, Humanized
nimotuzumab
Serum
Acetic Acid
Immunotherapy

Keywords

  • Lu
  • EGFR
  • h-R3
  • monoclonal antibodies
  • Nimotuzumab
  • radioimmunotherapy
  • radiolabeling

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology

Cite this

Preclinical evaluation of 177Lu-Nimotuzumab : A potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors. / Vera, Denis Rolando Beckford; Eigner, Sebastian; Beran, Milos; Henke, Katerina Eigner; Laznickova, Alice; Laznicek, Milan; Melichar, Frantisek; Chinol, Marco.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 26, No. 3, 01.06.2011, p. 287-297.

Research output: Contribution to journalArticle

Vera, Denis Rolando Beckford ; Eigner, Sebastian ; Beran, Milos ; Henke, Katerina Eigner ; Laznickova, Alice ; Laznicek, Milan ; Melichar, Frantisek ; Chinol, Marco. / Preclinical evaluation of 177Lu-Nimotuzumab : A potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors. In: Cancer Biotherapy and Radiopharmaceuticals. 2011 ; Vol. 26, No. 3. pp. 287-297.
@article{ecfc8f4a33634a87a23840f1e3bd05e8,
title = "Preclinical evaluation of 177Lu-Nimotuzumab: A potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors",
abstract = "Background: The humanized monoclonal antibody Nimotuzumab (h-R3) has demonstrated an exceptional and better clinical profile than other monoclonal antibodies for immunotherapy of epidermal growth factor receptor-overexpressing tumors. This work deals with the preparation and radiolabeling optimization of 177Lu-Nimotuzumab and their preclinical evaluation. Methods: Nimotuzumab was conjugated with S-2-(4-isothiocyanatobenzyl)-1,4,7,10- tetraazacyclododecane tetraacetic acid (p-SCN-Bn-DOTA), testing different molar ratios. The immunoconjugates were characterized. The radiolabeling with 177Lu was optimized. Radioimmunoconjugates stability was tested in 2-[bis[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid (DTPA) excess and human serum. In vitro studies were performed in tumor model cell lines. Receptor-specific binding was tested by competitive inhibition. 177Lu-Nimotuzumab in vivo studies were conducted in healthy and xenograft animals. Results: Nimotuzumab conjugates were obtained with high purity. Radiolabeling yield and specific activities ranged from 63.6{\%} to 94.5{\%} and from 748 to 1142 MBq/mg, respectively. The stability in DTPA excess and human serum was 95.9{\%} and 93.2{\%} after 10 days, respectively. The radioimmunoconjugate showed specific receptor binding in tumor cell lines. Biodistribution in healthy animals showed the typical behavior of the immunoconjugates based on monoclonal antibodies. The study in xenografts mice demonstrated uptake of 177Lu-Nimotuzumab in the tumor and reticuloendothelial organs. Conclusions: 177Lu-Nimotuzumab was obtained with high purity and specific activities under optimal conditions without significant loss in immunoreactivity and might be a potential radioimmunoconjugate for radioimmunotherapy of tumors with epidermal growth factor receptor overexpression.",
keywords = "Lu, EGFR, h-R3, monoclonal antibodies, Nimotuzumab, radioimmunotherapy, radiolabeling",
author = "Vera, {Denis Rolando Beckford} and Sebastian Eigner and Milos Beran and Henke, {Katerina Eigner} and Alice Laznickova and Milan Laznicek and Frantisek Melichar and Marco Chinol",
year = "2011",
month = "6",
day = "1",
doi = "10.1089/cbr.2010.0916",
language = "English",
volume = "26",
pages = "287--297",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Preclinical evaluation of 177Lu-Nimotuzumab

T2 - A potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors

AU - Vera, Denis Rolando Beckford

AU - Eigner, Sebastian

AU - Beran, Milos

AU - Henke, Katerina Eigner

AU - Laznickova, Alice

AU - Laznicek, Milan

AU - Melichar, Frantisek

AU - Chinol, Marco

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Background: The humanized monoclonal antibody Nimotuzumab (h-R3) has demonstrated an exceptional and better clinical profile than other monoclonal antibodies for immunotherapy of epidermal growth factor receptor-overexpressing tumors. This work deals with the preparation and radiolabeling optimization of 177Lu-Nimotuzumab and their preclinical evaluation. Methods: Nimotuzumab was conjugated with S-2-(4-isothiocyanatobenzyl)-1,4,7,10- tetraazacyclododecane tetraacetic acid (p-SCN-Bn-DOTA), testing different molar ratios. The immunoconjugates were characterized. The radiolabeling with 177Lu was optimized. Radioimmunoconjugates stability was tested in 2-[bis[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid (DTPA) excess and human serum. In vitro studies were performed in tumor model cell lines. Receptor-specific binding was tested by competitive inhibition. 177Lu-Nimotuzumab in vivo studies were conducted in healthy and xenograft animals. Results: Nimotuzumab conjugates were obtained with high purity. Radiolabeling yield and specific activities ranged from 63.6% to 94.5% and from 748 to 1142 MBq/mg, respectively. The stability in DTPA excess and human serum was 95.9% and 93.2% after 10 days, respectively. The radioimmunoconjugate showed specific receptor binding in tumor cell lines. Biodistribution in healthy animals showed the typical behavior of the immunoconjugates based on monoclonal antibodies. The study in xenografts mice demonstrated uptake of 177Lu-Nimotuzumab in the tumor and reticuloendothelial organs. Conclusions: 177Lu-Nimotuzumab was obtained with high purity and specific activities under optimal conditions without significant loss in immunoreactivity and might be a potential radioimmunoconjugate for radioimmunotherapy of tumors with epidermal growth factor receptor overexpression.

AB - Background: The humanized monoclonal antibody Nimotuzumab (h-R3) has demonstrated an exceptional and better clinical profile than other monoclonal antibodies for immunotherapy of epidermal growth factor receptor-overexpressing tumors. This work deals with the preparation and radiolabeling optimization of 177Lu-Nimotuzumab and their preclinical evaluation. Methods: Nimotuzumab was conjugated with S-2-(4-isothiocyanatobenzyl)-1,4,7,10- tetraazacyclododecane tetraacetic acid (p-SCN-Bn-DOTA), testing different molar ratios. The immunoconjugates were characterized. The radiolabeling with 177Lu was optimized. Radioimmunoconjugates stability was tested in 2-[bis[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid (DTPA) excess and human serum. In vitro studies were performed in tumor model cell lines. Receptor-specific binding was tested by competitive inhibition. 177Lu-Nimotuzumab in vivo studies were conducted in healthy and xenograft animals. Results: Nimotuzumab conjugates were obtained with high purity. Radiolabeling yield and specific activities ranged from 63.6% to 94.5% and from 748 to 1142 MBq/mg, respectively. The stability in DTPA excess and human serum was 95.9% and 93.2% after 10 days, respectively. The radioimmunoconjugate showed specific receptor binding in tumor cell lines. Biodistribution in healthy animals showed the typical behavior of the immunoconjugates based on monoclonal antibodies. The study in xenografts mice demonstrated uptake of 177Lu-Nimotuzumab in the tumor and reticuloendothelial organs. Conclusions: 177Lu-Nimotuzumab was obtained with high purity and specific activities under optimal conditions without significant loss in immunoreactivity and might be a potential radioimmunoconjugate for radioimmunotherapy of tumors with epidermal growth factor receptor overexpression.

KW - Lu

KW - EGFR

KW - h-R3

KW - monoclonal antibodies

KW - Nimotuzumab

KW - radioimmunotherapy

KW - radiolabeling

UR - http://www.scopus.com/inward/record.url?scp=79960052817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960052817&partnerID=8YFLogxK

U2 - 10.1089/cbr.2010.0916

DO - 10.1089/cbr.2010.0916

M3 - Article

C2 - 21711096

AN - SCOPUS:79960052817

VL - 26

SP - 287

EP - 297

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 3

ER -